Navigation Links
ABILIFY approved for acute treatment of bipolar I disorder in patients 10 to 17 years old
Date:2/29/2008

TOKYO, JAPAN & PRINCETON, NEW JERSEY, FEBRUARY 29 -- Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application for ABILIFY (aripiprazole) for the acute treatment of manic and mixed episodes associated with Bipolar I Disorder, with or without psychotic features in pediatric patients (10 to 17 years old). ABILIFY has been approved for the acute and maintenance treatment of manic and mixed episodes associated with Bipolar I Disorder with or without psychotic features in adults since September 2004 and March 2005, respectively.

Pediatric bipolar illness is a serious condition, said Christoph Correll, M.D., Medical Director, Recognition and Prevention Program, The Zucker Hillside Hospital and Assistant Professor of Psychiatry and Behavioral Sciences, Albert Einstein College of Medicine, Glen Oaks, New York. The availability of an additional treatment option that can help guide decisions in managing Bipolar I Disorder in children and adolescents is welcome news.

The approval is based on results from a four-week, multicenter, randomized, double-blind, placebo-controlled study in pediatric patients (10 to 17 years old) with Bipolar I Disorder that demonstrated efficacy with ABILIFY compared to placebo on the primary efficacy endpoint, mean change from baseline to Week 4 on the Young-Mania Rating Scale (Y-MRS) Total Score.

We are pleased that the FDA has approved ABILIFY to treat pediatric patients aged 10 to 17 years suffering from Bipolar I Disorder, said Taro Iwamoto, Ph.D., Chief Executive Officer, President and Chief Operating Officer, Otsuka Pharmaceutical Development and Commercialization, Inc. The approval of this new indication for ABILIFY provides clinicians with expanded treatment options that can help address the therapeutic needs of this population.

We are committed to developing innova
'/>"/>

Contact: Debra Kaufmann
debra.kaufmann@otsuka.com
240-683-3568
Otsuka America Pharmaceutical, Inc.
Source:Eurekalert

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. US FDA approves ABILIFY for adolescent patients with schizophrenia
2. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for Adolescent Patients With Schizophrenia
3. ABILIFY(R) (aripiprazole) Supplemental New Drug Application for the Treatment of Pediatric Patients with Bipolar I Disorder Accepted for Priority Review by the U.S. Food and Drug Administration
4. FDA approves ABILIFY(R) (aripiprazole) as the first medication for add-on treatment of MDD
5. $52.5 Million Settlement Against Sepracor Inc. Approved
6. FDA Cracks Down on Unapproved Cough Medicines
7. Video: New FDA-Approved Sun Protectant Saves Skin All Year Round
8. Optometry-Backed Vision Care for Kids Act Approved by U.S. House
9. Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis
10. A fresh look at existing therapies: Researchers explore ways to teach approved drugs new tricks
11. Barrs Generic Version of Estrostep(R) Fe Tablets Approved

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)...Logic today announced MathMagic Personal Edition 4...tor. With a focus on the equation quality and ease...e equation editor for mathematical equations and s...y standard mathematical expressions including LaTe...Docs and Zoho Writer, and other enhanced features....
(Date:12/4/2009)...ibOx, a leading developer of novel and effective c...d forces with MolPort, an innovator in rare chemic...mical trading platform and builds database of comm...database and its updates to computational chemists...tual screening procedures. Once they identify suit...
(Date:12/4/2009)...h American Seminars Inc. is now accepting medical ...ucation courses at their medical facility in 2010....eration and capabilities to the medical community ...heir physical therapy and occupational therapy tea...250 live training events. , ...
(Date:12/4/2009)...lliSoft Group offers their new IntelliChoice upgra...ialing software, IntelliSoft Group is the only ven...oyment option. ,SaaS is an excellent option for th...ints, yet are in need of medical credentialing sof... 4, 2009 -- ISG Group, LLC, doing business as Inte...
(Date:12/4/2009)...tar fasciitis heel pain affects over two million p...rapy has been cited by the American Academy of Ort... In response to these findings, Orthotics And Bey...rapy systems for plantar fasciitis treatment as a ... therapies. , (PRWEB) Dec...
Breaking Medicine News(10 mins):Health News:MathMagic Personal 4.8 for Windows Now Supports Google Docs and Zoho Equation 2Health News:MathMagic Personal 4.8 for Windows Now Supports Google Docs and Zoho Equation 3Health News:MathMagic Personal 4.8 for Windows Now Supports Google Docs and Zoho Equation 4Health News:InhibOx and Molport Join Forces to Deliver Integrated Lead Design and Delivery 2Health News:InhibOx and Molport Join Forces to Deliver Integrated Lead Design and Delivery 3Health News:North American Seminars Inc. Opens Its 2010 Physical Therapy Continuing Medical Education Course Sponsorship Program 2Health News:North American Seminars Inc. Opens Its 2010 Physical Therapy Continuing Medical Education Course Sponsorship Program 3Health News:North American Seminars Inc. Opens Its 2010 Physical Therapy Continuing Medical Education Course Sponsorship Program 4Health News:IntelliSoft Group Focuses on Protecting Customer Investment in Medical Credentialing Systems -- Budget Constraints and Forced Upgrades in Medical Credentialing Automation 2Health News:Orthotics And Beyond Introduces Compressive Cold Therapy Products for Plantar Fasciitis Treatment 2
...aching Offers Relief to Families Nationwide, SHOR...,life coach and certified parent coach, Tammy Gold...d children at a New York City mental health,clinic...ir upbringing were the real issues. The demands an...
...ney General on physician evaluations will have,nat...atement is,attributable to Nancy H. Nielsen, M.D.,...al Association (AMA) welcomes today,s announcement...king programs. Aetna,s decision to join CIGNA in a...
... iFire Technology Corp., CALGARY, Nov. 13 /PRNews...d today that for the third quarter ended September... or 18 cents per share, on revenues of,$7.8 millio...uarter of 2007, the Company recorded reorganizatio...
...plications for humans, researchers say , TUESDAY,...ydrate diet slowed prostate tumor growth, possibly...sulin production, U.S. researchers say. , "This st...mplications for prostate cancer therapy through so...
...en people with diabetes are walking around in the ...foot problems that could lead to amputation, accor...e International Journal of Clinical Practice. , ...ys that ulceration can have serious implications f...
...3, 2007 For the millions of Americans whose nativ... road block to quality healthcare, according to a ...hers in the Center for Health Policy Research in t...cal errors and lower patient satisfaction. , In...
Other Medicine News:Health News:New Practice Brings Sanity and Support to Parents 2Health News:AMA Commends Aetna for Quality First Commitment 2Health News:Westaim announces 2007 third quarter results 2Health News:Westaim announces 2007 third quarter results 3Health News:Westaim announces 2007 third quarter results 4Health News:Low-Carb Diet May Slow Prostate Tumor Growth 2Health News:63 percent of diabetics risk serious foot problems by wearing the wrong-sized shoes 2Health News:Language barriers adversely impact health-care quality 2
(Date:12/3/2009)...Pa., Dec. 3 Radiology imaging lead...d integration capabilities at the November 2009 Ra... Connect.PACS(TM) product, enabling the first rad...e latest release in the company,s newly branded C... http://www.newscom.com/cgi-bin/prnh/20091203/NE...
(Date:12/3/2009)... In response to the incr...echnologies in the evolving healthcare delivery sy...r Health Informatics (DCHI) to provide a campus fo...nnovative interdisciplinary approach to education ...nurses and healthcare administrators with an exper...
(Date:12/3/2009)... Apnex Medical, Inc., a private me...ted a second round of private equity financing tot...ete a clinical study and develop a second generati...ned to treat obstructive sleep apnea (OSA). ,, ...iates, New Enterprise Associates (NEA), Polaris Ve...
Breaking Medicine Technology:MEDRAD Demonstrates PACS Injection-Record Integration at RSNA 2009 2MEDRAD Demonstrates PACS Injection-Record Integration at RSNA 2009 3Duke Medicine to Train Healthcare Professionals in Health Informatics 2Duke Medicine to Train Healthcare Professionals in Health Informatics 3Apnex Medical, Inc. Raises Additional $14 Million 2Apnex Medical, Inc. Raises Additional $14 Million 3InfoLogix Selected by Hilo Medical Center for Multi Year Engagement to Deliver Wireless as a Service 53837 1InfoLogix Selected by Hilo Medical Center for Multi Year Engagement to Deliver Wireless as a Service 53837 2InfoLogix Selected by Hilo Medical Center for Multi Year Engagement to Deliver Wireless as a Service 53837 3Living in U S May Raise Hispanics Cancer Risk 53835 1Living in U S May Raise Hispanics Cancer Risk 53835 2Living in U S May Raise Hispanics Cancer Risk 53835 3Oncothyreon announces webcast of second quarter 2009 financial results conference call 13414 1
...s Corporation (Nasdaq: DVAX ) today reported that...weed allergy therapy, to subjects as,part of an en...d to enroll,a total of 300 subjects. Subjects are ...gy and a positive skin test. Exposure to ragweed a...se individuals with confirmed,ragweed allergic dis...
...nsistently Positive Clinical ...ta presented today from,Abbott,s SPIRIT III U.S. p...ive, statistically significant clinical results fo...nt System at one year, including continued,clinica...E) and continued,non- inferior rates of target ves...
Other Medicine Technology:Dynavax Begins TOLAMBA(TM) Environmental Exposure Chamber Study 2Dynavax Begins TOLAMBA(TM) Environmental Exposure Chamber Study 3Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial 2Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial 3Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial 4Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial 5
House Teflon Coated Elevator
Cleft Palate Elevator
Louisville Elevator
Converse Periosteal Elevator
Medicine Products: